Price T Rowe Associates Inc Replimune Group, Inc. Transaction History

Price T Rowe Associates Inc

$883 Billion
Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 10,819,209 shares of REPL stock, worth $56.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

10,819,209

Previous 10,853,832 0.32%

Holding current value

$56.8 Million

Previous $106 Million 5.02%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.92 - $10.38 $239,591 - $359,386	-34,623 Reduced 0.32%	10,819,209 $101 Million
Q1 2025 May 14, 2025	SELL	$9.75 - $14.31 $1.06 Million - $1.56 Million	-109,051 Reduced 0.99%	10,853,832 $106 Million
Q4 2024 Feb 14, 2025	BUY	$10.54 - $14.93 $11.4 Million - $16.2 Million	1,083,633 Added 10.97%	10,962,883 $133 Million
Q3 2024 Nov 14, 2024	BUY	$8.09 - $11.23 $5.2 Million - $7.22 Million	643,193 Added 6.96%	9,879,250 $108 Million
Q2 2024 Aug 14, 2024	BUY	$5.01 - $9.46 $13.5 Million - $25.4 Million	2,687,127 Added 41.03%	9,236,057 $83.1 Million
Q1 2024 May 15, 2024	BUY	$6.87 - $9.31 $4.81 Million - $6.51 Million	699,679 Added 11.96%	6,548,930 $53.5 Million
Q4 2023 Feb 14, 2024	BUY	$6.75 - $16.18 $378,351 - $906,921	56,052 Added 0.97%	5,849,251 $49.3 Million
Q3 2023 Nov 14, 2023	BUY	$15.96 - $22.18 $960,584 - $1.33 Million	60,187 Added 1.05%	5,793,199 $99.1 Million
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $3.72 Million - $5.72 Million	237,396 Added 4.32%	5,733,012 $133 Million
Q1 2023 May 15, 2023	BUY	$17.48 - $29.09 $7.53 Million - $12.5 Million	430,872 Added 8.51%	5,495,616 $97.1 Million
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $15.3 Million - $24.9 Million	893,573 Added 21.42%	5,064,744 $138 Million
Q3 2022 Nov 14, 2022	SELL	$15.6 - $21.15 $26.7 Million - $36.2 Million	-1,711,360 Reduced 29.09%	4,171,171 $72 Million
Q2 2022 Aug 15, 2022	SELL	$13.32 - $19.98 $1.87 Million - $2.8 Million	-140,229 Reduced 2.33%	5,882,531 $103 Million
Q1 2022 May 16, 2022	BUY	$15.24 - $29.75 $2.35 Million - $4.59 Million	154,122 Added 2.63%	6,022,760 $102 Million
Q4 2021 Feb 14, 2022	BUY	$25.43 - $34.25 $3.86 Million - $5.19 Million	151,598 Added 2.65%	5,868,638 $159 Million
Q3 2021 Nov 15, 2021	BUY	$28.98 - $39.54 $18.8 Million - $25.6 Million	647,590 Added 12.77%	5,717,040 $169 Million
Q2 2021 Aug 16, 2021	BUY	$28.5 - $39.37 $56.7 Million - $78.4 Million	1,991,208 Added 64.69%	5,069,450 $195 Million
Q1 2021 May 17, 2021	BUY	$30.22 - $45.57 $13.7 Million - $20.6 Million	452,551 Added 17.24%	3,078,242 $93.9 Million
Q4 2020 Feb 16, 2021	BUY	$23.5 - $52.65 $61.7 Million - $138 Million	2,625,691 New	2,625,691 $100 Million

Others Institutions Holding REPL

# of Institutions

195

Shares Held

77.7M

Call Options Held

2.06M

Put Options Held

2.86M

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $259M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Replimune Group, Inc. Transaction History